Literature DB >> 17254507

HIV-1 vaccine development: progress and prospects.

Anna R Thorner1, Dan H Barouch.   

Abstract

The development of a prophylactic HIV-1 vaccine is a global health priority. It has proven extraordinarily challenging, however, to develop immunogens that elicit broadly reactive HIV-1-specific neutralizing antibodies. As a result, most HIV-1 vaccine candidates in development focus on generating virus-specific cellular immune responses. Both plasmid DNA vaccines and recombinant live vectors have been shown to elicit cellular immune responses, and vaccine candidates based on these technologies are now being evaluated for safety, immunogenicity, and efficacy in advanced phase clinical trials. This review examines the progress and prospects of these vaccine strategies.

Entities:  

Year:  2007        PMID： 17254507     DOI： 10.1007/s11908-007-0025-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  50 in total

1.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

2.  Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Authors:  Angelique A C Lemckert; Shawn M Sumida; Lennart Holterman; Ronald Vogels; Diana M Truitt; Diana M Lynch; Anjali Nanda; Bonnie A Ewald; Darci A Gorgone; Michelle A Lifton; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.

Authors:  J C Learmont; A F Geczy; J Mills; L J Ashton; C H Raynes-Greenow; R J Garsia; W B Dyer; L McIntyre; R B Oelrichs; D I Rhodes; N J Deacon; J S Sullivan
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

5.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

6.  Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

Authors:  Shawn M Sumida; Paul F McKay; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Michael S Seaman; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Norman L Letvin; Dan H Barouch
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

7.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103
View more
  16 in total

1.  Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.

Authors:  Antonio Valentin; Agneta von Gegerfelt; Margherita Rosati; Georgios Miteloudis; Candido Alicea; Cristina Bergamaschi; Rashmi Jalah; Vainav Patel; Amir S Khan; Ruxandra Draghia-Akli; George N Pavlakis; Barbara K Felber
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

2.  Anti-gamma interferon antibodies enhance the immunogenicity of recombinant adenovirus vectors.

Authors:  Shawn S Jackson; Jörn E Schmitz; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

3.  AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.

Authors:  Norman G Jones; Allan DeCamp; Peter Gilbert; Michael L Peterson; Marc Gurwith; Huyen Cao
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

4.  A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.

Authors:  For Yue Tso; Federico G Hoffmann; Damien C Tully; Philippe Lemey; Robert A Rasmussen; Hong Zhang; Ruth M Ruprecht; Charles Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

Review 5.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

6.  Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.

Authors:  Lingshu Wang; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Masaru Kanekiyo; David Einfeld; Richard M Schwartz; C Richter King; Jason G D Gall; Gary J Nabel
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

7.  Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.

Authors:  Jinyan Liu; Bonnie A Ewald; Diana M Lynch; Matthew Denholtz; Peter Abbink; Angelique A C Lemckert; Angela Carville; Keith G Mansfield; Menzo J Havenga; Jaap Goudsmit; Dan H Barouch
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

8.  Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.

Authors:  Ilnour Ourmanov; Takeo Kuwata; Robert Goeken; Simoy Goldstein; Ranjani Iyengar; Alicia Buckler-White; Bernard Lafont; Vanessa M Hirsch
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

9.  Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.

Authors:  David Cooper; Kevin J Wright; Priscilla C Calderon; Min Guo; Farooq Nasar; J Erik Johnson; John W Coleman; Margaret Lee; Cheryl Kotash; Irene Yurgelonis; Robert J Natuk; R Michael Hendry; Stephen A Udem; David K Clarke
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

10.  Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.

Authors:  Margherita Rosati; Antonio Valentin; Rashmi Jalah; Vainav Patel; Agneta von Gegerfelt; Cristina Bergamaschi; Candido Alicea; Deborah Weiss; Jim Treece; Ranajit Pal; Phillip D Markham; Ernesto T A Marques; J Thomas August; Amir Khan; Ruxandra Draghia-Akli; Barbara K Felber; George N Pavlakis
Journal:  Vaccine       Date:  2008-04-21       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.